University of Maryland Dermatology

Topics

• Dermatology and Skin Diseases 273
• Psoriasis: Treatment and Pathogenesis 229
• Cutaneous Melanoma Detection and Management 73
• Nonmelanoma Skin Cancer Studies 53
• Cutaneous lymphoproliferative disorders research 49
• Dermatologic Treatments and Research 44
• Hair Growth and Disorders 33
• melanin and skin pigmentation 31
• Autoimmune Bullous Skin Diseases 30
• Cancer Immunotherapy and Biomarkers 29
• Nail Diseases and Treatments 26
• Hidradenitis Suppurativa and Treatments 25

Most cited

1. Psoriasis.

   Nature reviews. Disease primers · 2025 · 152 citations · Andrew Blauvelt

2. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).

   The British journal of dermatology · 2021 · 502 citations · Andrew Blauvelt

3. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.

   The New England journal of medicine · 2023 · 275 citations · Andrew Blauvelt

4. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.

   Journal of the American Academy of Dermatology · 2023 · 292 citations · Andrew Blauvelt

5. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.

   Lancet (London, England) · 2021 · 463 citations · Andrew Blauvelt

6. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.

   JAMA dermatology · 2021 · 414 citations ·